Yara Abdou: Navigating Treatment pathways in Metastatic HR+ Breast cancer
Yara Abdou shared a post on X:
“With the expanding arsenal of endocrine & targeted therapies, treating HR+ HER2- MBC requires seamless integration of clinical, molecular & patient-specific factors to deliver personalized & effective care.
Check out our latest article in Journal of Clinical Oncology on navigating treatment pathways in HR+MBC.”
Authors: Prarthna V. Bhardwaj and Yara Abdou.
Source: Yara Abdou/X
Yara Abdou, MD, specializes in the treatment of early stage and metastatic breast cancer. Her research focuses on the development of novel therapies, particularly immunotherapy, to treat different subtypes of breast cancer. She works closely with basic and translational scientists to study the breast tumor microenvironment and find ways to enhance treatment approaches by utilizing the immune system. In addition, her research also focuses on racial differences in tumor biology and immune microenvironment, to better understand racial disparities and improve clinical outcomes in minority women with breast cancer. As a clinician and a researcher, her goal is to improve treatment strategies for breast cancer while minimizing suffering and morbidity from the disease.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023